公开(公告)号：EP2140874A1

公开(公告)日：2010-01-06

申请号：EP08740701.1

申请日：2008-04-21

申请人： Nihon Pharmaceutical Co., Ltd.

发明人： SASAKI, Tetsuya ,  HARA, Naoko ,  ISHIKAWA, Makoto

IPC分类号： A61K38/00 ,  A61P1/16

CPC分类号： A61K38/1709

摘要： When acute hepatitis progresses to fulminant hepatitis, a large amount of hepatic cells are rapidly broken, and as a result, the prognosis is seriously worsened. Thus, it is important to prognose the progress of acute hepatitis into fulminant hepatitis at an early stage and quickly start an appropriate treatment therefor. Although the prognosis of progress into fulminant hepatitis becomes possible owing to recent advances in test methods and diagnostic techniques, there has been no appropriate prophylactic/therapeutic agent for fulminant hepatitis. The present invention provides a therapeutic agent for acute hepatitis or a prophylactic/therapeutic agent for fulminant hepatitis with little side effect. The problem of the invention was solved by using a composition containing apolipoprotein A-II.

摘要翻译： 当急性肝炎发展为爆发性肝炎，大量的肝细胞的迅速破裂，并且作为结果，预后严重恶化。 因此，在预测急性肝炎到爆发性肝炎的进展，在早期阶段，并开始迅速适当治疗为此是非常重要的。 虽然由于在测试方法和诊断技术的最新进展的进展预后成暴发性肝炎成为可能，出现了对暴发性肝炎没有适当的预防/治疗剂。 本发明提供了用于急性肝炎或副作用少暴发性肝炎的预防/治疗剂的治疗剂。 本发明的通过使用含有载脂蛋白A-II的组合物是什么解决了这个问题。